- Home
- CPOP vs TCRX Comparison
CPOP vs TCRX Comparison
Compare CPOP & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPOP
- TCRX
- Stock Information
- Founded
- CPOP 2007
- TCRX 2018
- Country
- CPOP China
- TCRX United States
- Employees
- CPOP N/A
- TCRX N/A
- Industry
- CPOP Services-Misc. Amusement & Recreation
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- CPOP Consumer Discretionary
- TCRX Health Care
- Exchange
- CPOP Nasdaq
- TCRX Nasdaq
- Market Cap
- CPOP 98.5M
- TCRX 91.7M
- IPO Year
- CPOP 2021
- TCRX 2021
- Fundamental
- Price
- CPOP $1.26
- TCRX $1.87
- Analyst Decision
- CPOP
- TCRX Strong Buy
- Analyst Count
- CPOP 0
- TCRX 6
- Target Price
- CPOP N/A
- TCRX $9.50
- AVG Volume (30 Days)
- CPOP 3.5M
- TCRX 244.7K
- Earning Date
- CPOP 09-02-2025
- TCRX 08-12-2025
- Dividend Yield
- CPOP N/A
- TCRX N/A
- EPS Growth
- CPOP N/A
- TCRX N/A
- EPS
- CPOP N/A
- TCRX N/A
- Revenue
- CPOP $65,186,721.00
- TCRX $6,961,000.00
- Revenue This Year
- CPOP N/A
- TCRX $159.20
- Revenue Next Year
- CPOP N/A
- TCRX N/A
- P/E Ratio
- CPOP N/A
- TCRX N/A
- Revenue Growth
- CPOP 108.29
- TCRX N/A
- 52 Week Low
- CPOP $0.46
- TCRX $1.02
- 52 Week High
- CPOP $2.47
- TCRX $6.23
- Technical
- Relative Strength Index (RSI)
- CPOP 64.84
- TCRX 58.85
- Support Level
- CPOP $0.79
- TCRX $1.63
- Resistance Level
- CPOP $0.92
- TCRX $1.86
- Average True Range (ATR)
- CPOP 0.22
- TCRX 0.11
- MACD
- CPOP 0.02
- TCRX 0.00
- Stochastic Oscillator
- CPOP 28.15
- TCRX 93.10
About CPOP Pop Culture Group Co. Ltd
Pop Culture Group Co Ltd hosts entertainment events, operates hip-hop-related online programs, and provides event planning and execution services and marketing services to corporate clients. It generates revenue from Event Hosting business by providing sponsorship packages to advertisers in exchange for sponsorship fees and by selling tickets for those concerts. The company has various operations services out of which Brand Promotion earns maximum revenue, following by Event Hosting, and Event Planning and Execution.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.